Evidence map›Paper›PMID 39821814›Full record

ArticleEJNMMI research2025

Yilin Li, Rongxi Wang, Jingci Chen, Zhaohui Zhu, Yu Wang, Wenbin Ma

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06412952 (68Ga-NOTA-RM26 PET/CT in Glioma Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06412952 early_phase1unknown statusnot on this map

68Ga-NOTA-RM26 PET/CT in Glioma Patients

TypeinterventionalSponsorPeking Union Medical College HospitalRan2022 to 2024Enrolled30ConditionsGliomaArms68Ga-RM26
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antitumor efficacy and safety of locoregional [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yilin Li *Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Rongxi Wang *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Jingci ChenDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Zhaohui ZhuChinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. 13611093752@163.com.
Yu WangDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. ywang@pumch.cn.
Wenbin MaDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. mawb2001@hotmail.com.

Funding

Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2021-I2M-1-014Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2021-I2M-1-016Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2022-I2M-2-002Chinese Academy of Medical Science Innovation Fund for Medical Sciences 2022-I2M-C&T-A-008National Natural Science Foundation of China 82151302National Natural Science Foundation of China 82272046the National High Level Hospital Clinical Research Funding 2022-PUMCH-A-019the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-113the National High Level Hospital Clinical Research Funding 2022-PUMCH-C-004the National High Level Hospital Clinical Research Funding 2022-PUMCH-D-002
6 · The paper itself

Abstract

backgroundGliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of

resultsTwenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited

conclusionsThis study is the first application of

trial registrationClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952.

Indexed as

68Ga-NOTA-RM26Gastrin-releasing peptide receptor (GRPR)GliomaPET/CT

Identifiers

PMID39821814
PMCPMC11748694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.